

DAFTAR PUSTAKA

- Adhayani, F., D. Listyaningrum., dan H. Sjahrir. 2014. Gangguan Kognitif Penderita Penyakit Parkinson. *Neurona* .vol 31 no 2: 42-48
- Aarsland, D. and M.V. Kurz. 2010. The Epidemiology of Dementia Associated with Parkinson's disease. *Journal of the neurological sciences*.289(1-2).18-22
- Aarsland, D., K. Bronnick, and C. Williams-Gray. 2010. Mild cognitive impairment in parkinson disease: a multicenter pooled analysis. *Neurology* 2010; 75: 1062–1069.
- Ahmad, B. 2015. *Gejala non motorik penyakit Parkinson*. Dalam *Penyakit Parkinson dan Gangguan Gerak Lainnya*. Buku panduan dan tatalaksana. Editor: Syamsudin T., Subagya., Akbar M. Kelompok studi movement disorders. Perdossi. Jakarta. pp 33-64
- Alves, G., K.F. Padersen., and J.P. Larsen. 2015. *Biomarker for cognition impairment and dementia in Parkinson's disease*. In *Cognitive impairment and dementia in Parkinson's disease*. Edited by Emre M. 2nd Ed. United Kingdom. Oxford University Press. Chapter 11: 17-151
- Basrand, MD. 2019. *Hubungan derajat penyakit parkinson dengan fungsi kognitif menggunakan instrumen Mini Mental State Examination (MMSE)*. <http://scholar.unand.ac.id/id/eprint/43805>
- Caccappolo, E. and K. Marder. 2015. *Epidemiology., diagnosis., and correlates of mild cognitive impairment in parkinson's disease*. In *Cognitive Impairment and Dementia in Parkinson's Disease*. . Edited by Emre M. 2nd Ed. United Kingdom. Oxford University Press. Chapter 16: pp 204-218
- Carranza, M., M. Snyder., J.D. Shaw., T.A. Zeslewicz. 2013. Epidemiology., Diagnosis., and pathophysiology of Parkinson's disease. In *Parkinson's disease A guide to medical treatment*. Italy; SEEd.Chapter 1.Pp.7-48
- Caspel, G.C., T. Simuni., T.D.Tosun ., I.W. Wu ., Y. Zhang., M. Nalls et al. 2017. Multiple Modality biomarker Prediction of Cognitive Impairment in prospectively followed de novo Parkinson disease. *PLoS ONE journal*.12(5): pp.1-18
- Cereda, E., R. Cilia., C. Klersy., C. Siri., B. pozzi., E. Reali et al. 2016. Dementia in Parkinson's disease : Is male gender a risk factor?. *Elsevier. Parkinsonism and related disorders*.xxx :pp 1-6
- Cerry, S., L. Mus., and F. Blandini. 2019. Parkinson's disease in women and men: what 's the difference ?. *Journal of parkinson's disease* 9: pp 501-515

- Collins, L.M. and C.H. Williams. 2016. The genetic basis of cognitive impairment and dementia in Parkinson's disease. *Frontiers in Psychiatry*. Vol 7;89:1-10
- Compta, Y., M.J. Martí., and B.N. Ibarretxe. 2009. Cerebrospinal tau., phospho tau and beta amyloid and neuropsychological functions in parkinson's disease. *Mov disord journal* 24: 2203-2210
- Cornelius, C., R. Crupi., V. Calabrese., A. Graziano., P. Milone., G. Pennisi et al. 2013. Traumatic brain injury: oxidative stress and neuroprotection. *Antioxidant & Redox Signaling.*, 19(8); 836-853
- Cosgrove, J. and J.E. Alty. 2018. Cognitive Deficits in Parkinson's disease : Current Perspective. *Journal of Parkinsonism and Restless Legs Syndrome*;8;1-11
- Crosgrave, J., J.E. Alty., S. Jamieson. 2015. Cognitive impairment in parkinson's disease. *British Medical Journal*.1-10
- Credle, J.J., J.L. George ., J. Wills ., V. Duka ., K. Shah ., Y.C. Lee et al. 2015. GSK-3beta dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and alpha-synuclein. *Cell Death Differentiation*. 22(5):838-51
- Dahlan, M.S. 2011. Penelitian Prognostik dan Sistem Skoring: Disertai Praktik dengan SPSS dan stata. Seri 8. Jatinagor; Alqaprint . Bab 3: 25-36
- Dahlan, M.S. 2017. *Penelitian Diagnostik., Validitas & Reliabilitas; Dasar-dasar teoretis dan Aplikasi dengan Program SPSS dan Stata*. Edisi 2. Jakarta; Epidemiologi Indonesia. Bab 11: 179-182
- Dewati, E., D. Tunjungsari ., N.R. Ariarini. 2017. Penyakit parkinson. Dalam Buku *Ajar Neurologi FKUI*. Editor: Aninditha T., Wiratman W. Jakarta. Penerbit Kedokteran Indonesia;109-135
- Dewey. 2000. Clinical features of parkinson disease. In : *Parkinson Disease and Movement Disorders*. New Jersey; Humana press.pp 71-84
- Donaghy, P.C., L.G. McKeith . 2014. The Clinical characteristic of dementia with lewy bodies and a consideration of prodromal diagnosis. *Alzheimer's research and therapy*.6:46
- Emre, M. 2015. *General features., mode of onset., and course of dementia in Parkinson's disease*. In *Cognitive impairment and dementia in Parkinson's disease*. Oxford University Press. Chapter 3 : 17-27
- Fahn, S., J. Jancovic . 2007. *Parkinsonisme: Clinical Feature and Differential Diagnosis*. In *Principles and practice of Movement Disorders*. Philadeilphia: Elsevier: 79-95

- Fontoura, J. L., C. Baptista, F.D. Brito, P. D. Brito, P. D. Brito. 2017. Depression in parkinson's disease : The contribution from animal studies. *Hindawi parkinson's disease* vol 18: pp 1-9
- Furman, J.L., J.A. Vaquer., C.L. White., N.J. Cairns., P.T. Nelson., M.I. Diamond. 2017. Widespread tau seeding activity at early braak stages. *Acta neuropathol*:133 (1):91-100
- Goldman, S.M. and C.M. Tanner. 2015. Epidemiology of *parkinson's disease*. In *Parkinson's disease and Movement Disorders*. Wolters Kluwers.1-132
- Guerrero, B.E., X. Luo., J. Schmeidler., A. Michael., K. Dahlman., H.T. Grossman. et al. 2009. The MMSE orientation for time domain is a strong predictor of subsequent cognitive decline in the elderly. *Int J Geriatr Psychiatry*. ;24(12):1429–37.
- Haggerty, T., J. Credle., O. Rodriguez., J. Wills., A.W. Oaks., E. Masliah et al. 2011. Hyperphosphorylated Tau in an a-synuclein-overexpressing transgenic model of Parkinson's disease. *Eur J Neurosci*. 33:1598–610.
- Hall, S., Y. Surova., A. Ohrfelt., H. Zetterberg., D. Lindqvist., O. Hansson. 2015. CSF biomarker and clinical progression of parkinson disease. *American academy of neurology*.84:57-63
- Hanna-Pladdy, B., K. Jones., R. Cabanban., R. Pahwa., K.E. Lyons. 2013. Predictors of Mild Cognitive Impairment in Early-Stage Parkinson's Disease. *Dementia Geriatr Cogn Dis Extra* ;3:168–78
- Hanriko, R. and B.P. Anzani. 2018. Penyakit Parkinson: Ancaman Kesehatan Bagi Komnitas pertanian. *J agromedicine*. Vol 5.no 1.pp 508-512
- Horvath, J., F.R. Herrmann., P.R. Burkhard., C. Bouras., E. Kovari. 2013. *Parkinsonism and Related Disorders*. Elsevier. 19;864-868
- Husni, A., A. Suryamiharja., B. Ahmad., D. Purwasamatra. 2013. Buku Panduan Tatalaksana Penyakit Parkinson dan Gangguan Gerak Lainnya. Editor: Husni A., Suryamiharja A., Ahmad B., Purwasamatra., Akbar M., Tumewah R., dkk Depok . Perdossi.
- Jankovic, J. and E.K. Tan. 2020., Parkinson's Disease: etiopathogenesis and treatment. *J Neurol Neurosurg Psychiatry* 2020;91:795-808
- Johnson, G. and W. Stoothoff. 2004. Tau Phosphorylation in neuronal cell function and dysfunction. *Journal of Cell Science*.117;5721-5729
- Kalia, L.V. 2017. Biomarkes for cognitive Dysfunction in Parkinson's disease. *Parkinsonism and related disorders*. *J.parkreldis*.Suppl:1:S19- S23
- Karthick, N., K.N. Poornima., A. Saravanan., D. Alwind., P. Venkataraman. 2016. Phosphorylation of tau protein in brain region of chronic renal failure-

induced Rats: Ameliorative effect of erythropoietin. *Asian Journal of pharmaceutical and clinical research* vol 9. Hal 392-397

- Kierzynka, A., R. Kazmierski., W. Kozubski. 2011. Educational level and cognitive impairment in patient with parkinson disease. *Neurologia i neurochirurgia polska*: 45.1:24-31
- Kochhann, R., M.O. Cerveira., C. Godinho., A. Camozzato., M.LF. Chaves. 2009. Evaluation of Mini-Mental State Examination scores according to different age and education strata., and sex., in a large Brazilian healthy sample. *Dement e Neuropsychol.* (2):88–93.
- Kouli, A., K.M. Torsney., W.L. Kuan. 2018. *Parkinson's disease: etiology, neuropathology, and pathogenesis.* In *Parkinson's disease: Pathogenesis and clinical aspects*. Edited by Stoker TB., Greenland JC. Brisbane. Codon Publication. Chapter 1: pp:3-26
- Kulisevsky, J., J. Pagonabarraga .2009. Cognitive Impairment in Parkinson's Disease : Tool for Diagnosis and assessment. *Movement Disorders.* Vol 24 No.8. pp 1103-1110
- Larasanti, P., P. Samatra., S.Y. Trisnawati ., K. Sumada. 2020. Karakteristik Klinis dan Derajat Berat Gejala Motorik Penyakit Parkinson di RSUP Sanglah dan RSUD Wangaya Denpasar. *Callosum Neurology.* Vol 3 No 1;pp 6-11
- Larner, A.J. 2008. *Neurodegeneratif disorders.* In *Neuropsychological Neurology ., The Neurocognitive Impairments of Neurological Disorders.* United Kingdom. Cambridge University Press. 2: 69
- Lin, J.S., T. Baumeister., S. Garg., M. J McKeown. 2018. Cognitive profiles and hub Vulnerability in Parkinson's disease. *Frontiers in Neurology.* Vol 9.482
- Liu, Z ., T. Zhou., A.C. Ziegler., P. Dimitrion., L. Zuo. 2017. Oxidative stress in Neurodegenerative Disease: From Molecular Mechanism to clinical application. *Oxidative Medicine and Cellular Longevity.* Hindawi;1-12
- Liu, Z., Li-Peifu., J. Wu., Y. Wang., Li-Ping., X. Hou et al. 2015. The Cascade of Oxidative Stress and Tau Protein Autophagic Dysfunction in Alzheimer's Disease. *Intech.* Chapter 2.28-45
- Lukasiewicz, J.C., M.M. Malodobra., A. Zimny., L. Noga L., B. Paradowski. 2020. Plasma Tau protein and A β level as markers of cognitive impairment in patients with parkinson's disease. *Adv Clin Exp Med*;29(1);115-121
- Magrinelli, F., A. Picelli., P. Tocco., A. Federico., L. Roncari., N. Smania et al. 2016. Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. *Hindawi*:1–18.
- Magniven, J. 2009. Psychological services for people with parkinson's disease. *The british psychological Society.* pp 1-15

- Maiti, P., J. Manna., and G.L. Dunbar. 2017. Current Understanding of The Molecular Mechanism in Parkinson's Disease: Targets for potential treatments. *Translational Neurodegeneration open access*. BioMed Central 6;28. pp 1-35
- Mars, L. 2016. Depression and Parkinson's disease; Current Knowledge. *HHS Public Access.Curr Neurol Neurosci:13(12):409*
- Maschke, S.S., N. Sergeant., C.M. Dhaenens., S. Bombois., V. Deramecourt., M.L.C. Boudin et al. 2008. Tau as biomarker of neurodegenerative disease. *Biomarkers Med;2(4): 363-384*
- Massano, J. 2012. Clinical approach to Parkinson's Disease : Features., Diagnosis., and Principles of Management. Cold Spring Harbor Perspectives in Medicine. Pp 1-15
- Maulana, R. dan V.P. Kalanjati. 2012. Kontribusi inflamasi terhadap patogenesis penyakit Parkinson. *Majalah Biomorfologi.vol 25 no 2 ; pp 27-32*
- Mayza, A dan D.N. Lastri. 2017. Neurobehavior dasar dan pemeriksaannya. In *Buku Ajar Neurologi*. Editor: Aninditha T.,Wiratman W. Penerbit Kedokteran Indonesia. Jakarta.vol 1
- Mei-Chen, C ., J. Liang-Liu., Y. Ru-wu., C.C Yi.,C.H. Shing., M. Ling-Cheng., C.D. Yee. 2009 Increase oxidative damage in peripheral blood correlates with severity of Parkinson's disease. Elsevier; *Journal neurobiology of disease* 33; 429-435
- Metta, V., K. Logishetty., P.M. Martin., H.M. Gage., P.E.S. Schartau., T.K. Kaluarachchi *et al*. 2011. The Possible Clinical Predictors of Fatigue in Parkinson's Disease: A study of 135 Patienta As Part of International Non Motor Scale Validation Project. Hindawi. *Parkinson's Disease*.Vol 2011: pp1-7
- Miocinovic, S., S. Somayajula., S. Chitnis., J.L Vitek. 2013. Hystory., aplication and mechanism of deep brain stimulation. *JAMA Neurology.,70(2).163*
- Mink, J.W. 2015. *Functional Organization of The Basal Ganglia*. In *Parkinson's Disease & Movement Disorders*. Ed 6th Edited by Jancovic J.,Tolosa E. Wolters Kluwer. Philadelphia. Chapter 1; 32-44
- Miranda, B.R. and J.T. Greenamyre. 2017. *Etiology and pathogenesis of parkinson's disease*. In *Oxidative stress and redox signalling in parkinson's disease*.*Issues in toxicology*. Editor: Franco R., Doorn JA., Rochet JC. Royal society of chemistry. chapter 1: pp.1-26
- Mohamad, W.N.A., N. Che-Din., N. Ibrahim. 2015. Cognitive profiles in parkinson's disease and their correlation with dementia., anxiety and depression: A preliminary study. *Malay J Med*.Dec 2015: 29-35

- Mollenhauer, B. 2016. Biological counfounders for the values of cerebrospinal fluid proteins in parkinson's disease and related disorders. *Journal of neurochemistry*. 10.1-28
- Montine, T.J., M. Shi., J.F. Quinn ., E.R. Pesking., S. Craft., C. Gingham et al. 2010. CSF A β ₄₂ and tau in Parkinson's disease with cognitive impairment. *Journal of Mov Disord*.25(15);2682-2685
- Ohm, T.G. and V. Meske. 2006. Cholesterol., statins and tau. *Acta Neurol Scand* : 114 (Suppl. 185): 93–101
- Painous, C. and M.J. Marti. 2020. Cognitive impairment in Parkinson's disease: What we know so far?.*Research and reviews in parkinsonism* 2020:10. Pp 7-17
- Papagno, C and L.Trojano. 2017. Cognitive and behavioral disorders in Parkinson's disease: An Update. I: Cognitive Impairments. *Review article. Springer*;1-9
- Porowska, A.M., U. Wasik., M. Goras., A. Filipek., G. Niewiadomska. 2014. Tau Protein Modification and Interaction: Their Role in Function and dysfunction. *International Journal of Molecular Sciences*. Mar:15(3): 4671-4713
- Przedborski, S. 2015. *Etiology and Pathogenesis of Parkinson's Disease*. In *Parkinson's Disease & Movement Disorders* . Ed 6th Edited by Jancovic J.,Tolosa E. Wolters Kluwer. Philadelphia Chapter 7 pp.162-195
- Ransmayr, G. 2015. Cognitive Impairment In Parkinson's disease. *Psychiatria Danubina.,Medicinska Naklada*. Croatia. vol 27. No 4 pp 458-461
- Rhodes, S.W., R.A. Barker., C.H. Williams. 2015. *The pathophysiological and prognostic heterogeneity of mild cognitive impairment in parkinson's disease*. In *Cognitive Impairment and Dementia In Parkinson's disease*. 2nd edition.Edited by Emre M. United Kingdom. Oxford university press. Chapter:17: 224-236
- Rowland, R. 2000. *Parkinsonism*. In: Houston H., Rowland LP., editors. Merritt's Neurology. 10th ed.New York. Lippincott Williams & Wilkins;. p. 515–7
- Roy, B., G.R. Jackson. 2014. Interactions between Tau and alpha-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease. *Hum Mol Genet*. 23:3008–23
- Salama, M., A. Shalash., A. Magdy., M. Makar., T. Roushdy., M. Elbalkimy. 2018. Tubulin and Tau: Possible targets for diagnosis of Parkinson's and Alzheimer's diseases. United states. *Plos One journal*;1-11
- Sauerbier, A., K.R. Chaudhuri. 2015. *Nonmotor Symptoms In Parkinson's Disease*. In *Parkinson's Disease & Movement Disorders*. Ed 6th chapter 6; pp137-161

- Soetedjo and H.H. Martono. *Gangguan neurologik pada usia lanjut. Buku ajar Boedhi Darmojo Geriatri (Ilmu kesehatan usia lanjut)* 4 th ed. Jakarta: Balai Penerbit FKUI ., 2011. P3.,518
- Tarukbua, F.R., R. Tumewah R. dan J. Maja. 2016. Gambaran Fungsi Kognitif penderita parkinson di poliklinik saraf RSUP Prof.Dr.R.D.Kandou Manado. *Journal e clinic*.volume 4;1-7
- Watson, G.S and J.B Leverenz. 2011. Profil of cognitive impairment in Parkinson disease. *NIH Public Access*.PMC:1-11
- Waxman, E.A., B.I. Giasson. 2011. Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds., and provides novel insights into the hyperphosphorylation of tau. *J Neurosci Offic J Soc Neurosci*. 31:7604–18
- Whitfield, D., M.A. Piggot., E.K. Perry., P.T Francis. 2015. Neurochemical pathology of Parkinson's Disease dementia and Dementia Lewi Bodies. In *Cognitive Impairment and Dementia in Parkinson's Disease*. Ed 2th Edited by: Emre M. Oxford., United Kingdom.chapter 14; pp177-194
- Winer, J.R., A. Maass., P. Pressman., J. Stiver., D.R. Schonhaut., S.Z. Baker et al. 2017. Associations Between Tau., β -Amyloid., and Cognition in Parkinson Disease. University of Adelaide library. *Jama neurology*;72:2;227-235
- Yang, Y., B. Tang ., J. Guo J. 2016. Parkinson's disease and cognitive impairment. *Hindawi publishing corporation.parkinson's disease* vol 2016;1-8
- Zhang, X ., F. Gao F., D. Wang D., C. Li ., Y. Fu., W. He., J. Zhang. 2018. Tau Pathology in Parkinson's disease. *Frontier in Neurology*. Vol 8; 809
- Zwilling, Y.A, N.B. Ly., Q. Xu., G. Li G., A. Bernardo., S.Y. Yoon et al. 2010. Apolipoprotein E4 Causes Age- and Tau-Dependent Impairment of GABAergic Interneurons., Leading to Learning and Memory Deficits in Mice. *The Journal of Neuroscience* ; 30(41):13707–13717